Company: ZLAB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038548
Chunk: 88

Company: Zai Lab Ltd
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 88
---
 Months Ended June 30,ChangeSix Months Ended June 30,Change20252024$%20252024$%ZEJULA41,042 44,999 (3,957)(9)%90,571 90,500 71 — %VYVGART / VYVGART Hytrulo26,497 23,190 3,307 14 %44,602 36,352 8,250 23 %NUZYRA14,292 12,295 1,997 16 %29,410 22,208 7,202 32 %OPTUNE12,355 12,584 (229)(2)%23,718 25,064 (1,346)(5)%QINLOCK8,536 7,038 1,498 21 %17,045 13,131 3,914 30 %XACDURO4,622 — 4,622 NM5,739 — 5,739 NMAUGTYRO1,399 — 1,399 NM3,025 — 3,025 NMOther (i)342 — 342 NM625 — 625 NMTotal product revenue, net109,085 100,106 8,979 9 %214,735 187,255 27,480 15 %

NM - Not Meaningful

(i)Other includes product candidates sold in patient programs prior to commercialization. 

Our product revenue is primarily derived from the sales of our commercial products primarily in mainland China, net of sales returns and rebates to distributors with respect to the sales of these products. 

22

Our net product revenue increased by $9.0 million and $27.5 million in the three and six months ended June 30, 2025, respectively, primarily due to higher sales of VYVGART, driven by an extension of duration of therapy and increasing market penetration, XACDURO, which was launched since the fourth quarter of 2024, and NUZYRA, supported by increasing market coverage and penetration. These higher sales were partially offset by softer sales of ZEJULA, due to evolving competitive dynamics within the PARPi class. 

Cost of Product Revenue

Cost of product revenue increased by $7.9 million and $12.7 million in the three and six months ended June 30, 2025,